|
BioScreening - organic compounds for screening
News: CollaborationsBioFocus and University of Bristol enter drug discovery collaboration in chronic pain - Saffron Walden and Bristol, UK; 16 July 2010 – BioFocus and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol. Total [...]
NIH Prolongs Compound-Management Arrangement with Galapagos Until End of 2012 - NIH has extended its agreement with Galapagos’ service division, BioFocus, for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012. Galapagos will thus be eligible to receive up to $8.6 million over the course of the two-year extension. The NIH MLSMR collects samples for high-throughput biological screening and distributes them to [...]
Aquapharm and AMRI Enter into a Novel Marine Chemistry Collaboration - Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its extensive collection of marine micro-organisms.Under the terms of this agreement, drawing on its substantial experience [...]
Asterand Signs Agreement with Amylin Pharmaceuticals BioMAP(R) Platform will screen peptides for therapeutic potential - Asterand plc /quotes/comstock/23s!e:atd (UK:ATD 13.25, 0.00, 0.00%) , a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery, today announces that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a one-year collaboration agreement with Amylin [...]
Molecular Templates and ImClone Systems Form Oncology Drug Discovery and Translation Research Collaboration - GEORGETOWN, Texas, Jul 06, 2010 (BUSINESS WIRE) — Molecular Templates announced today that it has entered into a collaborative oncology drug discovery and translation research agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company. Under the terms of the agreement, Molecular Templates will identify Engineered Toxin Bodies (ETBs) against an undisclosed oncology [...]
GSK and Online Communities Create Unique Alliance to Stimulate Open Source Drug Discovery for Malaria - - GSK becomes first company to freely share chemical structures on 13,500 molecules from its compound library - Alliances formed with leading scientific research communities from private industry and public-domain data provider May 19, 2010/Burlingame, CA/ GlaxoSmithKline (GSK) had teamed up with leading public-domain data providers European Bioinformatics Institute (EMBL-EBI), the U.S. National Library of Medicine [...]
Evotec OAI and Serono Sign Assay Development and Screening Services Agreement - Hamburg, Germany/ Abingdon, UK/ Geneva, Switzerland – Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening programmes to the pharmaceutical and biotechnology industries, has announced a services agreement with Serono S.A. (SWX: SEO, NYSE: SRA). Under the terms of the agreement, Evotec OAI will [...]
Evotec Gains Access to Hypha’s MycoDiverse Natural Products Library - Evotec negotiated access to U.K.-based Hypha Discovery’s MycoDiverse™ fungi-derived natural product screening library. The deal means Evotec will be able to offer the library to clients through its hit and lead identification services. Hypha currently has access to over 2,500 strains of higher basidiomycete and ascomycete fungi, many from South American and South East Asian [...]
Collaboration with GSK for Inflammatory Diseases - Cellzome inked a drug discovery alliance with GlaxoSmithKline in the field of inflammatory disease with a €33 million (about $44.79 million) up-front payment. The deal represents the companies’ second drug discovery partnership and will focus on exploiting Cellzome’s Episphere™ technology for the identification of small molecule candidates against targets from four different epigenetic classes. The [...]
Evotec Signs High Throughput Screening Agreement With Active Biotech - Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a collaboration with Active Biotech AB (Stockholm:ACTI) to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Evotec will use its expertise and technologies in assay development, high throughput screening (HTS) and surface plasmon [...]
SGX Pharmaceuticals Announces Strategic Collaboration To Develop And Commercialize BCR-ABL Inhibitor - Under the terms of the agreement, SGX will receive from Novartis $25 million in upfront payments and the purchase of SGX common stock. Along with success-based milestones, but excluding royalties, total payments to SGX could exceed $515 million, including a minimum of two years of research funding. The success of Gleevec(TM) (imatinib), the first targeted [...]
AFraxis CEO Outlines Biotech’s Success With Ultra-Lean Pre-Clinical R&D in Russia - AFraxis, a mostly stealthy San Diego biotech, is getting ready to come out with a big announcement in the next week or so, but CEO Jay Lichter previewed some key parts of the story yesterday during a presentation before the San Diego Venture Group. He says the biotech has completed pre-clinical testing of a promising [...]
Evotec Extends and Broadens Research Agreement with Cubist Pharmaceuticals - Evotec AG / Evotec Extends and Broadens Research Agreement with Cubist Pharmaceuticals processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. - Collaboration expanded to include integrated fragment-based drug discovery activities on additional antibacterial targets – Hamburg, Germany – 25 February 2010: Evotec AG (Frankfurt Stock Exchange: [...]
Genentech and UCSF’s Small Molecule Discovery Center Ink Deal Targeting Neurodegenerative Diseases - The University of California, San Francisco and Genentech are partnering to discover and develop drug candidates for neurodegenerative diseases. The company will support the work of several researchers at the UCSF Small Molecule Discovery Center (SMDC) to progress prior SMDC research and Genentech discoveries. In addition to receiving financial support for its research function, UCSF [...]
Eli Lilly and GlaxoSmithKline: A Tale of Two Different Pharmas - New models for drug development, especially in big pharma, are being experimented by different companies. Eli Lilly (LLY) and GlaxoSmithKline (GSK) have two different models. These models do not throw out the old ones – but do offer additional routes going forward. Lilly has a Phenotypic Drug Discover Initiative, (or PD2), launched in 2009. Lilly [...]
iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer - iThemba Pharmaceuticals’ service division and Pyxis Discovery announced today that they have signed a collaborative agreement to jointly market both companies’ services. Pyxis’s world class computational chemistry and lead discovery expertise will be coupled with iThemba’s service division to provide medicinal and synthetic chemistry support to projects identified through Pyxis’ international client network. iThemba Pharmaceuticals [...]
Syntopix edges closer to early revenue streams, announces positive phase II cosmetic study of antimicrobial compound - Specialty antimicrobial research and development company Syntopix (AIM: SYN) took another step closer to commercialising a new product targeting a large consumer healthcare market, reporting good results from the trials of its new compound for the treatment of acneic skin, a condition that affects 85% of the population during their lifetime. Over the course of [...]
GSK Signs On Astex in Broad Partnership for About $33M Up Front - GlaxoSmithKline (GSK) has inked a deal with Astex Therapeutics to discover, develop, and commercialize compounds directed against multiple targets for £20 million (about $33 million) up front. Astex is eligible to development and regulatory milestones of over £300 million (roughly $496.47 million) if all programs are successfully developed and commercialized. The up-front payment comprises £12.5 [...]
Aeolus Drug Protects the Gastrointestinal Tract in Acute Radiation Syndrome Studies Sponsored by the National Institutes of Health`s National Institute for Allergy and Infectious Diseases - * AEOL 10150 Effectively Increases Regeneration of GI Stem Cells and Reduces the Severity and Duration of Diarrhea * Drug Improves Survival When Administered 24 Hours after Total Body Irradiation MISSION VIEJO, Calif.--(Business Wire)-- Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today that recent experiments in preclinical models conducted by the National Institutes of Health`s (NIH), [...]
Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc - * Galapagos to discover small molecule candidate drugs for pre-clinical development in atherosclerosis* Total alliance milestones more than double to over EUR 400 million, plus royalties on worldwide sales Mechelen, Belgium 14 October 2009 – Galapagos NV (Euronext: GLPG) announced today that it has expanded its global strategic alliance in metabolic diseases with an affiliate [...]
|
|
